Aratana Therapeutics Inc (NASDAQ:PETX) insider Craig A. Tooman sold 30,000 shares of the stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $5.27, for a total transaction of $158,100.00. Following the completion of the sale, the insider now owns 75,024 shares in the company, valued at $395,376.48. The transaction was disclosed in a filing with the SEC, which is available through this link.

Aratana Therapeutics Inc (PETX) traded down $0.07 during trading on Friday, hitting $5.22. 263,256 shares of the stock traded hands, compared to its average volume of 613,722. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.08 and a current ratio of 3.42. The stock has a market cap of $224.46, a PE ratio of -3.60 and a beta of 3.36. Aratana Therapeutics Inc has a 12-month low of $4.81 and a 12-month high of $8.30.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.03. The firm had revenue of $6.16 million for the quarter, compared to analysts’ expectations of $6.47 million. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The business’s quarterly revenue was up 1440.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.38) EPS. equities research analysts forecast that Aratana Therapeutics Inc will post -1.03 EPS for the current year.

PETX has been the topic of several recent analyst reports. HC Wainwright initiated coverage on shares of Aratana Therapeutics in a research note on Friday, November 17th. They issued a “buy” rating and a $10.00 target price on the stock. Jefferies Group set a $9.00 target price on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research note on Thursday, November 16th. Zacks Investment Research upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research note on Thursday, November 9th. Stifel Nicolaus reiterated a “hold” rating and issued a $6.00 target price on shares of Aratana Therapeutics in a research note on Monday, December 18th. Finally, CL King initiated coverage on shares of Aratana Therapeutics in a research note on Wednesday, December 27th. They issued a “neutral” rating on the stock. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. Aratana Therapeutics currently has a consensus rating of “Hold” and an average target price of $8.55.

Institutional investors have recently bought and sold shares of the company. Voya Investment Management LLC raised its position in shares of Aratana Therapeutics by 22.7% during the 2nd quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 3,610 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Aratana Therapeutics by 7.2% during the 2nd quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 1,709 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Aratana Therapeutics during the 2nd quarter valued at $210,000. Parametric Portfolio Associates LLC raised its position in shares of Aratana Therapeutics by 6.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 1,875 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in shares of Aratana Therapeutics by 25.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,176 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 6,898 shares in the last quarter. Hedge funds and other institutional investors own 73.76% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2018/01/12/craig-a-tooman-sells-30000-shares-of-aratana-therapeutics-inc-petx-stock.html.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.